T1	intervention 19 45	epirubicin plus paclitaxel
T2	control 60 92	epirubicin plus cyclophosphamide
T3	location 150 164	United Kingdom
T4	eligibility 397 474	Patients previously untreated with chemotherapy (except for adjuvant therapy)
T5	outcome-Measure 719 744	progression-free survival
T8	total-participants 849 852	705
T9	intervention-participants 863 866	353
T10	control-participants 883 886	352
T11	outcome 1049 1073	Objective response rates
T12	iv-bin-percent 1079 1082	65%
T13	cv-bin-percent 1104 1107	55%
T14	outcome 1185 1189	died
T15	outcome 1191 1228	Median progression-free survival time
T16	iv-cont-median 1233 1243	7.0 months
T17	cv-cont-median 1265 1275	7.1 months
T20	outcome 1351 1379	median overall survival time
T21	iv-cont-median 1384 1393	13 months
T22	cv-cont-median 1415 1424	14 months
T25	outcome 1544 1567	grade 3 and 4 mucositis
T26	iv-bin-percent 1569 1571	6%
T27	cv-bin-percent 1574 1576	2%
T28	outcome 1607 1634	grade 3 and 4 neurotoxicity
T29	iv-bin-percent 1636 1638	5%
T30	cv-bin-percent 1641 1643	1%
T7	outcome 1683 1729	progression-free survival and overall survival
T6	outcome-Measure 778 794	overall survival
T18	outcome-Measure 796 810	response rates
T19	outcome-Measure 816 824	toxicity
